Purinergic receptor-mediated effects of adenosine 5'-triphosphate in urological malignant diseases.
about
Purinergic signalling and cancerPurinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.Signalling molecules in the urotheliumNTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.Purinergic signalling: from discovery to current developments.Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancerDifferential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis.High dose of extracellular ATP switched autophagy to apoptosis in anchorage-dependent and anchorage-independent hepatoma cells.P2X7-mediated chemoprevention of epithelial cancers.Purinergic signalling in the urinary tract in health and disease.Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future.Purinergic signalling in the lower urinary tract.Discovery of purinergic signalling, the initial resistance and current explosion of interest.Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells.Purinergic Signalling: Therapeutic Developments.Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cellsRole of P2X7 purinoceptors in neuroprotective mechanism of ischemic postconditioning in mice.
P2860
Q24618782-F7049E8E-2EC0-48D8-887E-0C66F85C28A4Q33770947-4FFB9690-0768-43C3-809F-96C995A15B83Q33919264-7B477447-ACF6-4B68-AB6E-E942B96F8455Q34080499-1186C729-EA92-4C0C-B499-39CBC4250BC3Q34123241-D100B4A1-4A30-4499-A638-BC6A12BF4B8BQ34400146-F99A6726-22B5-4827-A09B-2308DF6AF661Q34633667-366848CB-1E47-4059-BC8F-62726D496AEFQ35040383-E30DDC25-434D-4592-A121-BE9F41331278Q35044543-3FA9EB98-FAB5-4DA5-8695-FC20230AFF12Q35941350-5712328D-F735-42F9-A3E4-A4AA018DF7CAQ37309831-775BE5D4-3C36-4A72-A0D1-C60744F11A61Q37468676-880EF504-79E9-4316-AB9E-8190D6CF0243Q37618815-F4ED93A5-D0AF-4CC3-973A-9359705B9D61Q37620260-817FC20A-79E8-4B81-85CB-DAACDAA2532CQ37975129-98AF7A81-2F9C-43BC-A3FB-5610FD72DB18Q38061933-5DFFBF2B-5D58-47D7-B2FA-88CE80797C96Q41954765-2D189E0B-B178-4B39-9AAE-00185069643EQ42068171-C5A3EDB4-D8CE-4715-99A0-16924F39C264Q42316250-943EB229-FFB0-4F4B-9579-7E8B02C2A361Q42367885-DDAF024F-4EB6-4271-AB84-5A667B4868F4Q42427923-550F0A49-1472-49C6-BD6A-0ACCAD9ABD23Q50225669-55C94C7D-05B8-4B5F-BB6E-79D7526A3540
P2860
Purinergic receptor-mediated effects of adenosine 5'-triphosphate in urological malignant diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Purinergic receptor-mediated e ...... urological malignant diseases.
@en
Purinergic receptor-mediated e ...... urological malignant diseases.
@nl
type
label
Purinergic receptor-mediated e ...... urological malignant diseases.
@en
Purinergic receptor-mediated e ...... urological malignant diseases.
@nl
prefLabel
Purinergic receptor-mediated e ...... urological malignant diseases.
@en
Purinergic receptor-mediated e ...... urological malignant diseases.
@nl
P2860
P1476
Purinergic receptor-mediated e ...... urological malignant diseases.
@en
P2093
Geoffrey Burnstock
Majid Shabbir
P2860
P304
P356
10.1111/J.1442-2042.2008.02207.X
P577
2008-12-04T00:00:00Z